Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD)
Introduction and Objectives: Metabolic-associated fatty liver disease (MAFLD) poses a significant risk for progression to advanced liver diseases, underscoring the need for early detection. This study aims to assess and compare the diagnostic efficacy of non-invasive markers (APRI, FIB-4, Hepamet, a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268124002461 |
| _version_ | 1797272468055916544 |
|---|---|
| author | Bryan A. Priego-Parra Arturo Triana-Romero Raúl Bernal-Reyes María E. Icaza-Chávez Sophia E. Martínez-Vázquez Ana D. Cano-Contreras Héctor Vivanco-Cid José M. Remes-Troche |
| author_facet | Bryan A. Priego-Parra Arturo Triana-Romero Raúl Bernal-Reyes María E. Icaza-Chávez Sophia E. Martínez-Vázquez Ana D. Cano-Contreras Héctor Vivanco-Cid José M. Remes-Troche |
| author_sort | Bryan A. Priego-Parra |
| collection | DOAJ |
| description | Introduction and Objectives: Metabolic-associated fatty liver disease (MAFLD) poses a significant risk for progression to advanced liver diseases, underscoring the need for early detection. This study aims to assess and compare the diagnostic efficacy of non-invasive markers (APRI, FIB-4, Hepamet, and NAFLD Score (NFS) in detecting hepatic fibrosis among MAFLD patients. Materials and Patients: A retrospective examination was performed on adults with MAFLD who had undergone transient liver elastography. Hepatic fibrosis was identified at a cut-off point of ≥8 kPa. APRI, FIB-4, Hepamet, and NFS scores were evaluated with cut-off points determined via the Youden index. Receiver Operating Characteristic (ROC) curves and their areas were computed. All participants provided informed consent. Results: Our cohort consisted of 150 MAFLD patients, the median age of 55 years (48-65), comprising 66.2% (129) females and 33.88% (66) males. The median BMI was 32.1 (28.8-35.6), kPa was 5.6 (4.6-7.8), and CAP was 310 (280-341). Hepatic fibrosis was evident in 24.7% (37) of the participants. Among the evaluated scores, APRI exhibited superior diagnostic performance, achieving an area under the curve of 0.72, followed by FIB-4 (0.66), Hepamet (0.64), and NFS (0.62). The cut-off points of 0.50 for APRI, 1.65 for FIB-4, 0.05 for Hepamet, and -0.75 for NFS yielded sensitivities of 86%, 82%, 86%, and 81%, respectively (Fig 1). Conclusions: Non-invasive scoring systems, notably APRI, demonstrate valuable potential in evaluating hepatic fibrosis among Mexican MAFLD patients. Utilization of adjusted cut-off points enhances test efficiency, thereby facilitating early detection of individuals at greater risk of disease progression. |
| first_indexed | 2024-03-07T14:29:47Z |
| format | Article |
| id | doaj.art-214282805eec41cea28a55850920dd98 |
| institution | Directory Open Access Journal |
| issn | 1665-2681 |
| language | English |
| last_indexed | 2024-03-07T14:29:47Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Annals of Hepatology |
| spelling | doaj.art-214282805eec41cea28a55850920dd982024-03-06T05:26:13ZengElsevierAnnals of Hepatology1665-26812024-02-0129101452Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD)Bryan A. Priego-Parra0Arturo Triana-Romero1Raúl Bernal-Reyes2María E. Icaza-Chávez3Sophia E. Martínez-Vázquez4Ana D. Cano-Contreras5Héctor Vivanco-Cid6José M. Remes-Troche7Centro de Investigaciones Biomédicas, Universidad Veracruzana; Instituto de Investigaciones Médico-Biológicas, Universidad VeracruzanaUnidad Médica de Alta Especialidad (UMAE) Hospital de Especialidades ''Dr. Bernardo Sepúlveda Gutiérrez'', Centro Médico Nacional Siglo XXlGrupo de Investigación MAFLD de la Asociación Mexicana de GastroenterologíaGrupo de Investigación MAFLD de la Asociación Mexicana de GastroenterologíaGrupo de Investigación MAFLD de la Asociación Mexicana de GastroenterologíaInstituto de Investigaciones Médico-Biológicas, Universidad VeracruzanaInstituto de Investigaciones Médico-Biológicas, Universidad VeracruzanaInstituto de Investigaciones Médico-Biológicas, Universidad VeracruzanaIntroduction and Objectives: Metabolic-associated fatty liver disease (MAFLD) poses a significant risk for progression to advanced liver diseases, underscoring the need for early detection. This study aims to assess and compare the diagnostic efficacy of non-invasive markers (APRI, FIB-4, Hepamet, and NAFLD Score (NFS) in detecting hepatic fibrosis among MAFLD patients. Materials and Patients: A retrospective examination was performed on adults with MAFLD who had undergone transient liver elastography. Hepatic fibrosis was identified at a cut-off point of ≥8 kPa. APRI, FIB-4, Hepamet, and NFS scores were evaluated with cut-off points determined via the Youden index. Receiver Operating Characteristic (ROC) curves and their areas were computed. All participants provided informed consent. Results: Our cohort consisted of 150 MAFLD patients, the median age of 55 years (48-65), comprising 66.2% (129) females and 33.88% (66) males. The median BMI was 32.1 (28.8-35.6), kPa was 5.6 (4.6-7.8), and CAP was 310 (280-341). Hepatic fibrosis was evident in 24.7% (37) of the participants. Among the evaluated scores, APRI exhibited superior diagnostic performance, achieving an area under the curve of 0.72, followed by FIB-4 (0.66), Hepamet (0.64), and NFS (0.62). The cut-off points of 0.50 for APRI, 1.65 for FIB-4, 0.05 for Hepamet, and -0.75 for NFS yielded sensitivities of 86%, 82%, 86%, and 81%, respectively (Fig 1). Conclusions: Non-invasive scoring systems, notably APRI, demonstrate valuable potential in evaluating hepatic fibrosis among Mexican MAFLD patients. Utilization of adjusted cut-off points enhances test efficiency, thereby facilitating early detection of individuals at greater risk of disease progression.http://www.sciencedirect.com/science/article/pii/S1665268124002461 |
| spellingShingle | Bryan A. Priego-Parra Arturo Triana-Romero Raúl Bernal-Reyes María E. Icaza-Chávez Sophia E. Martínez-Vázquez Ana D. Cano-Contreras Héctor Vivanco-Cid José M. Remes-Troche Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) Annals of Hepatology |
| title | Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) |
| title_full | Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) |
| title_fullStr | Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) |
| title_full_unstemmed | Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) |
| title_short | Comparison of non-invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction-associated fatty liver disease (MAFLD) |
| title_sort | comparison of non invasive scores for the evaluation of liver fibrosis in subjects with metabolic dysfunction associated fatty liver disease mafld |
| url | http://www.sciencedirect.com/science/article/pii/S1665268124002461 |
| work_keys_str_mv | AT bryanapriegoparra comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT arturotrianaromero comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT raulbernalreyes comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT mariaeicazachavez comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT sophiaemartinezvazquez comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT anadcanocontreras comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT hectorvivancocid comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld AT josemremestroche comparisonofnoninvasivescoresfortheevaluationofliverfibrosisinsubjectswithmetabolicdysfunctionassociatedfattyliverdiseasemafld |